Marksans Pharma Ltd.

26th August, 2021

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: **MARKSANS**

To,
BSE Limited
P. J. Towers
Dalal Street
Mumbai – 400 001

Scrip Code: **524404**

PRESS RELEASE

Marksans Pharma Limited announces USFDA approval for Acetaminophen Extended-Release Tablets USP, 650 mg (OTC).

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Acetaminophen Extended-Release Tablets USP, 650 mg (OTC).

Acetaminophen Extended-Release Tablets are bioequivalent to the reference listed drug, Tylenol Extended-Release Tablets, 650 mg, of Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.

This product approval endorses the capability of Marksans to develop and deliver products on a high barrier platform technology of extended release tablets. Extended release is an advanced technology and is a solution to patient compliance to avoid repeated dosages at short intervals.

Marksans will manufacture the products at its USFDA approved state-of-the-art solid oral dosage facility located at Goa, India.

For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary